openPR Logo
Press release

Chronic Kidney Disease Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Tricida, Otsuka Pharmaceuticals, AstraZeneca

04-08-2024 08:30 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Chronic Kidney Disease Market and Epidemiology 2032: Treatment

The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.
DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Chronic Kidney Disease Market Report:
• The Chronic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In March 2024, Despite facing a setback two years ago when the FDA rejected its initial approval application with a complete response letter, Akebia remained steadfast in its belief in the potential of its oral chronic kidney disease (CKD) anemia medication, Vafseo. The FDA has now granted clearance for Vafseo, specifically for patients suffering from CKD-associated anemia who have been on dialysis for a minimum of three months. This decision has initiated a market competition between Akebia and GSK.
• According to Cheng et al., the global estimated prevalence of Chronic Kidney Disease is 13.4% (11.7-15.1%), and patients with end-stage kidney disease (ESKD) needing renal replacement therapy is estimated between 4.902 and 7.083 million
• According to Center of Disease control and Prevention, Chronic Kidney Disease is more common in people aged 65 years or older (38%) than in people aged 45-64 years (12%) or 18-44 years (6%)
• Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
• Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
• The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%)
• The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.

Chronic Kidney Disease Overview
Chronic kidney disease (CKD) is defined by reduced estimated glomerular filtration rate (eGFR

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Kidney Disease Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Tricida, Otsuka Pharmaceuticals, AstraZeneca here

News-ID: 3456446 • Views:

More Releases from DelveInsight Business Research

Familial Chylomicronemia Syndrome Market to Expand Significantly by 2034, States DelveInsight Report
Familial Chylomicronemia Syndrome Market to Expand Significantly by 2034, States …
DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome
Generalized Anxiety Disorder Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight
Generalized Anxiety Disorder Pipeline 2025: Therapies, MOA Insights, and Key Cli …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Generalized Anxiety Disorder pipeline constitutes 12+ key companies continuously working towards developing 15+ Generalized Anxiety Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Generalized Anxiety Disorder Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Generalized Anxiety
Primary Mitochondrial Myopathies Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight
Primary Mitochondrial Myopathies Pipeline 2025: MOA, ROA, FDA-Approved Drugs, an …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Mitochondrial Myopathies pipeline constitutes 4+ key companies continuously working towards developing 4+ Primary Mitochondrial Myopathies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Primary Mitochondrial Myopathies Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Mitochondrial
Chlamydia Infections Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight
Chlamydia Infections Pipeline 2025: Therapies Under Investigation, Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chlamydia Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Chlamydia Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Chlamydia Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also

All 5 Releases


More Releases for Chronic

Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030 This latest report researches the industry structure,
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991 This latest report researches the
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share
Boot chronic pain
For immediate release Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue. We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them